Market Overview

Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial

Share:
Related LLY
Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Premarket Biotech Digest: Gilead HIV, Eliquis Trial Errors, Clinical Trial Phases (Seeking Alpha)

Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer's disease. In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild Alzheimer's disease, but not in patients with moderate Alzheimer's disease.

Posted-In: News FDA

 

Related Articles (LLY)

Get Benzinga's Newsletters